Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
|
CN |
|
S
|
Samil Pharmaceutical Co Ltd
KRX:000520
|
KR |
|
Ventas Inc
NYSE:VTR
|
US |
|
BBTV Holdings Inc
TSX:BBTV
|
CA |
|
M
|
Microelectronics Technology Inc
TWSE:2314
|
TW |
|
S
|
SBW Life Sciences Co Ltd
KOSDAQ:151910
|
KR |
|
Elicio Therapeutics Inc
NASDAQ:ELTX
|
US |
|
Holland Colours NV
AEX:HOLCO
|
NL |
|
Aramark
NYSE:ARMK
|
US |
|
W
|
Wing Yip Food Holdings Group Ltd
KOSDAQ:900340
|
HK |
|
Y
|
YeaRimDang Publishing Co Ltd
KOSDAQ:036000
|
KR |
|
D
|
DevPort AB
STO:DEVP B
|
SE |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's stock price target?
Not Available
Beijing Sun-Novo Pharmaceutical Research Co Ltd doesn't have any price targets made by Wall Street professionals.
What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Revenue forecast?
Projected CAGR
17%
For the last 5 years the
compound annual growth rate for
Beijing Sun-Novo Pharmaceutical Research Co Ltd's revenue is
36%.
The projected
CAGR
for the next 3 years is
17%.
What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Operating Income forecast?
Projected CAGR
129%
For the last 5 years the
compound annual growth rate for
Beijing Sun-Novo Pharmaceutical Research Co Ltd's operating income is
28%.
The projected
CAGR
for the next 1 year is
129%.
What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Net Income forecast?
Projected CAGR
21%
For the last 5 years the
compound annual growth rate for
Beijing Sun-Novo Pharmaceutical Research Co Ltd's net income is
30%.
The projected
CAGR
for the next 3 years is
21%.
